Concurrent cetuximab and radiotherapy after docetaxel–cisplatin induction chemotherapy in stage III NSCLC: Satellite—A phase II study from the Swedish Lung Cancer Study Group

Autor: Erik Holmberg, Stefan Bergström, Brita Lödén, H. Rylander, G. Wichardt-Johansson, Sven-Börje Ewers, Andreas Hallqvist, O. Brodin, Gunnar Wagenius, Jan Nyman, K. Nilsson, Lars Ekberg, Christer Sederholm

Publikováno v: Lung Cancer. 71:166-172

Background: Several attempts to increase the locoregional control in locally advanced lung cancer including concurrent chemotherapy, accelerated fractionation and dose escalation have been made during the last years. As the EGFR directed antibody cet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f611fe068b40b4e2f9ac9c76640f78d1
https://doi.org/10.1016/j.lungcan.2010.05.011

Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer – A first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study

Autor: Rolf Lewensohn, Berit Wennberg, Ingmar Lax, Merete Paludan, Karl-Axel Johansson, Nina Levin, Kristina Nilsson, Christer Sederholm, Elisabeth Morhed, Morten Høyer, Giovanna Gagliardi, Signe Friesland, Pia Baumann, Lena Wittgren, Anders Traberg, Lars Ekberg, Jo-Aûsmund Lund, Ninni Drugge, Jan Nyman

Publikováno v: Baumann, P, Nyman, J, Høyer, M, Gagliardi, G, Lax, I, Wennberg, B, Drugge, N, Ekberg, L, Friesland, S, Johansson, K-A, Lund, J-S, Morhed, E, Nilsson, K K, Levin, N, Paludan, M, Sederholm, C, Hansen, A T, Wittgren, L & Lewensohn, R 2008, ' Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer-a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study ', Radiotherapy & Oncology, vol. 88, no. 3, pp. 359-367 . https://doi.org/10.1016/j.radonc.2008.07.019

In a retrospective study using stereotactic body radiotherapy (SBRT) in medically inoperable patients with stage I NSCLC we previously reported a local control rate of 88% utilizing a median dose of 15Gyx3. This report records the toxicity encountere

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4b0e4b185299de256629c2521c25d49
https://doi.org/10.1016/j.radonc.2008.07.019

Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer

Autor: Assad Chemaissani, Christian Manegold, Gunnar Wagenius, Kari Liippo, Wolfgang Dornoff, Willem W. ten Bokkel Huinink, Joachim von Pawel, N. v. Walree, Peter Drings, Karin Mattson, Sergio Ricci, Rolf A. Stahel, Christer Sederholm, Bengt Bergman, Piikko-Liisa Kellokumpu-Lehtinen

Publikováno v: Lung Cancer. 26:85-94

This randomized study was designed to determine the response rates, survival and toxicities of single-agent gemcitabine (GEMZAR) and a combination of cisplatin/etoposide in chemonaive patients with non-resectable, locally advanced or metastatic non-s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83efcb3eec62e84c1778f6e5aa90246e
https://doi.org/10.1016/s0169-5002(99)00067-7

Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy

Autor: Sverre Sörenson, Lars Ek, Birgitta Clinchy, Andrea Lindgren, Magnus Lindskog, Helena Fohlin, Christer Sederholm, Bengt Bergman, Kristina Lamberg

Aim of the study: The primary purpose of this study is to investigate if pretreatment plasma levels of vascular endothelial growth factor (VEGF) are predictive of the effect of celecoxib on survival in advanced non-small cell lung cancer (NSCLC) trea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da1a7594e433607bd1005b37b0bd33d6
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-88362

Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group

Autor: Lars Thaning, Lars Ek, Sverre Sörenson, Jaroslaw Kosieradzki, Sven-Olof Ydreborg, Erik Holmberg, Andrea Koch, Christer Sederholm, Bengt Bergman, Kristina Lamberg

Publikováno v: European journal of cancer (Oxford, England : 1990). 47(10)

Background: Increased expression of cyclooxygenase-2 (COX-2) is common in non-small cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and clinical phase II trials have indicated that the addition of the COX-2 inhibito

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d36472b520f2a5f8e458ab660c6011c0
https://pubmed.ncbi.nlm.nih.gov/21565487